ICRF Announces Two New Grants Opportunities for 2022-23

Israel Cancer Research Fund is delighted to be funding two new research grants this year. Grant applications are due by April 15, 2022.

The Special ICRF Initiative In Pediatric Cancer Research

This special ICRF research grant initiative has been established to encourage outstanding investigators in Israel to focus on and expand their research in cancers occurring in children, leading to a better understanding of pediatric cancers, new treatments and, ultimately, higher survival rates and reduced treatment- and tumor-related morbidity.

These grants are intended to support the research of established Israeli investigators working at institutions in Israel. Applications will only be considered from individuals who have completed at least three years of postdoctoral fellowship training (or the equivalent) on the date on which the grant is activated, and applicants are required to provide strong published or preliminary data in support of the proposed research.

At the present time, funds are currently in place for one grant, to be awarded for a period of three (3) years, with total costs of $240,000 ($80,000 per year). (We anticipate being able to secure funding to award additional grants under this special initiative, should the application scores warrant it.)

If you have already submitted an ICRF grant application for 2022-23, you may also apply for this special initiative. However, if both applications are selected for funding, you will only be allowed to receive one of them. A principal investigator currently funded by ICRF may apply for another ICRF grant only if the start date is after the current funding period ends.

Conquer Cancer (The ASCO Foundation)–ICRF Career Development Award

The Conquer Cancer–Israel Cancer Research Fund Career Development Award (CC-ICRF CDA) provides funding to Israeli clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program.

This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.

The CC-ICRF CDA is a three (3) year grant totaling $200,000 ($66,666 per year) to pay for personnel and/or research expenses, and travel to attend the Conquer Cancer Grants and Awards Ceremony at the ASCO Annual Meeting. One grant will be awarded for 2022. Application submissions in all oncology subspecialties are welcome.

All administration for this grant will be provided by Conquer Cancer in consultation with ICRF.